Becton Dickinson and (NYSE:BDX) had its target price upped by Argus to $235.00 in a report released on Thursday morning, The Fly reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock. The analysts noted that the move was a valuation call.

A number of other research firms have also weighed in on BDX. Wells Fargo & Company reissued a positive rating and set a $235.00 price objective (up previously from $225.00) on shares of Becton Dickinson and in a research note on Tuesday, October 24th. They noted that the move was a valuation call. Piper Jaffray Companies reissued a buy rating and set a $213.00 price objective on shares of Becton Dickinson and in a research note on Tuesday, September 12th. Morgan Stanley increased their price objective on Becton Dickinson and from $205.00 to $245.00 and gave the company an equal weight rating in a research note on Friday, November 3rd. Royal Bank of Canada reissued a sector perform rating and set a $230.00 price objective (up previously from $210.00) on shares of Becton Dickinson and in a research note on Friday, November 3rd. Finally, Stifel Nicolaus reissued a buy rating and set a $245.00 price objective on shares of Becton Dickinson and in a research note on Friday, November 3rd. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $218.36.

Shares of Becton Dickinson and (BDX) opened at $221.46 on Thursday. The firm has a market capitalization of $50,485.73, a P/E ratio of 23.34, a PEG ratio of 1.73 and a beta of 1.07. Becton Dickinson and has a 52 week low of $161.50 and a 52 week high of $229.68. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The business’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.12 earnings per share. sell-side analysts forecast that Becton Dickinson and will post 10.63 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be paid a $0.75 dividend. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date is Thursday, December 7th. This represents a $3.00 dividend on an annualized basis and a yield of 1.35%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 64.52%.

Hedge funds have recently made changes to their positions in the stock. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its holdings in Becton Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 240 shares in the last quarter. Parkside Financial Bank & Trust raised its holdings in Becton Dickinson and by 8.1% in the second quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock worth $133,000 after purchasing an additional 51 shares in the last quarter. Harfst & Associates Inc. raised its holdings in Becton Dickinson and by 46.4% in the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after purchasing an additional 221 shares in the last quarter. Harvest Fund Management Co. Ltd raised its holdings in Becton Dickinson and by 82.8% in the second quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock worth $146,000 after purchasing an additional 338 shares in the last quarter. Finally, Acrospire Investment Management LLC raised its holdings in Becton Dickinson and by 259.7% in the second quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock worth $162,000 after purchasing an additional 600 shares in the last quarter. 88.60% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/becton-dickinson-and-bdx-price-target-raised-to-235-00-at-argus/1770687.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

The Fly

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.